Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBIBP-Corv Third Dose in HIV Infected People
NCT05105295Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Status: unknown.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05105295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105295.